Date of Award

8-20-2023

Document Type

Dissertation

Degree Name

Doctor of Medical Science (DMSc)

Department

Department of Physician Assistant Medicine

First Advisor

Nicholas Barber, MD

Second Advisor

Britt Benn

Third Advisor

Justin M. Gambini

Abstract

Purpose: This research article aims to shed light on the pivotal role of pharmacogenetics in breast cancer treatment by examining genetic variations that influence the efficacy and toxicity of commonly used drugs. Furthermore, this study highlights the significance of personalized treatment approaches in optimizing patient outcomes.

Method: A comprehensive literature search was conducted using databases such as PubMed. Search terms included "pharmacogenetics," "breast cancer treatment," "genetic markers," and "adverse effects." This review critically analyzes relevant studies that focus on the impact of genetic variations on the response to drugs used in breast cancer treatment.

Results: The review of literature reveals a growing body of evidence suggesting that genetic variations significantly influence the pharmacokinetics, toxicity, and efficacy of drugs commonly employed in breast cancer treatment. Studies have highlighted the relevance of genetic markers in predicting severe toxicities associated with certain drugs and the potential for suboptimal response to therapy based on individual genetic profiles.

Purpose: This research article aims to shed light on the pivotal role of pharmacogenetics in breast cancer treatment by examining genetic variations that influence the efficacy and toxicity of commonly used drugs. Furthermore, this study highlights the significance of personalized treatment approaches in optimizing patient outcomes.

Method: A comprehensive literature search was conducted using databases such as PubMed. Search terms included "pharmacogenetics," "breast cancer treatment," "genetic markers," and "adverse effects." This review critically analyzes relevant studies that focus on the impact of genetic variations on the response to drugs used in breast cancer treatment.

Results: The review of literature reveals a growing body of evidence suggesting that genetic variations significantly influence the pharmacokinetics, toxicity, and efficacy of drugs commonly employed in breast cancer treatment. Studies have highlighted the relevance of genetic markers in predicting severe toxicities associated with certain drugs and the potential for suboptimal response to therapy based on individual genetic profiles.

Conclusion: The integration of pharmacogenetic testing into breast cancer treatment has the potential to revolutionize the field, enabling clinicians to tailor treatment plans to individual patients. By identifying patients at risk of adverse drug reactions or suboptimal drug response, personalized approaches can enhance treatment efficacy while minimizing unnecessary toxicities. However, challenges such as cost and accessibility of genetic testing must be addressed for widespread implementation.

Download

Share

COinS